To evaluate gnetin C’s clinical potential, in the current study, we assessed the efficacy of gnetin C-supplemented diets as MTA1-targeted interception using a unique transgenic mouse model (R26MTA1; Pten+/f; Pb-Cre+) representing high-risk early-stage prostate cancer. This evidence concerns the gene PTEN and prostate carcinoma.